ArticleRespirology case reports2021
Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.
Article in Respirology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis.Therapeutic innovation & regulatory science · 2026Article
- Case Report: Dasatinib-associated chylothorax and occultFrontiers in pharmacology · 2026Article
- Review
- Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports.Frontiers in pharmacology · 2025Article
- Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review.Translational cancer research · 2023Article
- An Unusual Case of Non-traumatic Chylothorax.Cureus · 2022Article
- Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia.The American journal of case reports · 2022Article
- Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022Article
- A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib.European journal of case reports in internal medicine · 2022Article
- Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.Respirology case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dasatinib is a potent and effective second-generation oral tyrosine kinase inhibitor that is clinically indicated for the treatment of imatinib-resistant or imatinib-intolerant breakpoint cluster region-Abelson (BCR-ABL)-positive chronic myeloid leukaemia (CML) or for Philadelphia chromosome-positive acute lymphocytic leukaemia. The most common adverse events associated with dasatinib therapy are skin rash, gastrointestinal upset, pancytopenia, pulmonary hypertension, and fluid retention, including pleural effusion. However, chylothorax secondary to dasatinib administration has rarely been reported. Although the underlying mechanism leading to dasatinib-induced chylothorax is uncertain, the preferred treatment options are usually supported with diuretics or systemic steroids. Moreover, the discontinuation of the drug is mandatory in refractory cases. Here, we present the case of a patient with dasatinib-induced chylothorax, and review the previously reported cases in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.